News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Biovest International, Inc. Study Backs Non-Hodgkin’s Lymphoma Anti-Cancer Vaccine
June 1, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Tampa Bay Business Journal -- Biovest International Inc. said a Phase III clinical study has shown that BiovaxID significantly prolonged disease-free survival in follicular non-Hodgkin’s lymphoma.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
MORE ON THIS TOPIC
Drug Development
Eroding Immunity: Vaccine Hesitancy and Cynicism With Paul Offit
May 8, 2025
·
1 min read
·
Lori Ellis
Gene therapy
CRISPR’s Casgevy on the Rise With More Gene Therapy Proof of Concept To Come in 2025
May 7, 2025
·
4 min read
·
Annalee Armstrong
Huntington’s disease
PTC Nosedives Despite Claiming Phase II Win for Huntington’s Hopeful
May 5, 2025
·
2 min read
·
Dan Samorodnitsky
Policy
HHS To Require Placebo-Controlled Trials for All New Vaccines in ‘Radical Departure’ From Past
May 1, 2025
·
3 min read
·
Heather McKenzie
